Clearpoint Neuro, INC Form 4 insider transactions

ClearPoint Neuro, Inc.'s Chief Financial Officer, Danilo D'Alessandro, was granted 66,273 restricted stock units, vesting over three years.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett was granted 147,275 restricted stock units, vesting over three years.

ClearPoint Neuro CEO Joseph Burnett sold 2,943 shares of common stock for a weighted average price of $15.57 per share, pursuant to a pre-arranged 10b5-1 trading plan.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett exercised 20,000 stock options and subsequently sold the acquired shares under a pre-arranged 10b5-1 trading plan.

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, acquired one share of common stock through the company's Employee Stock Purchase Plan at $9.57 per share.

ClearPoint Neuro, Inc.'s Chief Operating Officer, Mazin Sabra, acquired 386 shares of common stock through the company's Employee Stock Purchase Plan.

ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, acquired 407 shares of common stock through the company's Employee Stock Purchase Plan.

ClearPoint Neuro, Inc. CEO Joseph Burnett acquired 254 common shares at $9.57 each through the Employee Stock Purchase Plan.

ClearPoint Neuro Director Timothy T. Richards acquired 884 shares of common stock as compensation, increasing his beneficial ownership to 79,754 shares.

ClearPoint Neuro Director Pascal Girin acquired 502 shares of common stock at $13.68 per share as part of a compensation plan.

ClearPoint Neuro Director R. John Fletcher acquired 422 shares of common stock valued at $13.68 per share as part of his compensation plan.

ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, exercised 3,555 stock options at $8.1 per share, increasing his direct beneficial ownership.

ClearPoint Neuro CEO Joseph Burnett sold 26,463 shares of common stock for approximately $714,000 under a pre-arranged 10b5-1 trading plan.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, disposed of 7,480 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

ClearPoint Neuro Director R. John Fletcher acquired 265 shares of common stock as compensation, increasing his total beneficial ownership to 116,240 shares.

ClearPoint Neuro Director Pascal Girin acquired 315 shares of common stock at $21.79 per share as part of his compensation plan.

ClearPoint Neuro Director Timothy T. Richards acquired 555 shares of common stock at $21.79 per share as part of his compensation plan.

ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, acquired 376 shares of common stock at $10.15 per share through the company's Employee Stock Purchase Plan.

ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, acquired 1,608 shares of common stock at $10.15 per share through the company's Employee Stock Purchase Plan, effective June 30, 2025.

ClearPoint Neuro, Inc.'s Chief Operating Officer, Mazin Sabra, acquired 361 shares of common stock at $10.15 per share through the company's Employee Stock Purchase Plan.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett acquired 1,424 shares of common stock at $10.15 per share through the company's Employee Stock Purchase Plan.

ClearPoint Neuro, Inc. Director Timothy T. Richards acquired 934 shares of common stock on July 1, 2025, as part of his non-employee director compensation.

ClearPoint Neuro, Inc. Director Pascal E. R. Girin acquired 523 shares of common stock at $11.94 per share as part of his director compensation plan.

ClearPoint Neuro, Inc. Director R. John Fletcher acquired 484 shares of common stock on July 1, 2025, as part of his non-employee director compensation.

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., sold 10,000 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

ClearPoint Neuro, Inc.'s Chief Financial Officer, Danilo D'Alessandro, reported the disposition of 4,754 shares of common stock valued at $13.29 per share to cover tax withholding obligations related to the vesting of restricted stock.

ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, reported the disposition of 3,561 shares of common stock valued at $13.29 per share to cover tax withholding obligations related to restricted stock vesting.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported the disposition of 15,476 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett sold 21,247 shares of common stock on June 9, 2025, at a weighted average price of $13.29 per share, as part of a net share settlement of vested restricted stock units.

ClearPoint Neuro, Inc. Director Lynnette C. Fallon sold 10,200 shares of common stock on June 3, 2025, to satisfy tax obligations arising from the vesting of restricted stock units.